Metronomics Global Health Initiative

Home page > Publications > Papers of Interest > Metronomic in adult

Metronomic in adult

category count 15 billets

Cancer research, a field on the verge of a paradigm shift?

In this perspective piece, Ido Goldstein, Shalom Madar et Varda Rotter from the Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot , Israel, analyze the roots of the paradigm on which cancer research is based. Then, they propose that the field of cancer research would benefit from integrating normal and "out of the (...)

Are Beta Blockers New Potential Anticancer Agents?

Shahid Akbar and Mansour Saleh Alsharidah respectively from the Department of Pharmacology, College of Pharmacy, and Department of Physiology, College of Medicine; Qassim University, Buraidah, in Saudi Arabia have just published a review entitled "Are Beta Blockers New Potential Anticancer Agents?" in the Asian Pacific Journal of Cancer Prevention (...)

Drug Repurposing in Oncology—patient and health systems opportunities

The cost of cancer drugs is going through the roof. Reconsidering the large arsenal of drugs already available for other diseases as options for treating cancer is a unique opportunity for patients and for national healthcare systems. The continuing reduction in the cost of DNA sequencing is paving the way for ‘precision medicine’, and an increasing (...)

Editorial in JASA : Metronomic chemotherapy: an alternative and effective means of chemotherapy, ideal for developing countries.

Dr Hemonta Dutta, Associate Professor and in-charge of Pediatric Surgery, in the Assam Medical College & Hospital in Dibrugarh and MGHI member has recently published a recent editorial in the Journal of the Association odf Surgeons of Assam in Idian, entitled : Metronomic chemotherapy: an alternative and effective means of chemotherapy, ideal for (...)

Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy.

Y. Shaked and al. from the Israel Institute of Technology, The University of Texas M. D. Anderson Cancer Center and the Sunnybrook Research Institute have just published in Cancer Research an article entitled: Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy where they show the impact of metronomic (...)

Metformin as a Novel Component of Metronomic Chemotherapeutic Use: A Hypothesis

In this hypothesis paper the authors Jorge Eduardo Duque, Juliana Velez, Ismael Samudio and Enoch Lai from the Grupo de Terapia Celular y Molecular, Pontificia Universidad Javeriana, Bogotá DC, Colombia, the Centro Oncológico de Antioquia, Medellín, Colombia and the Shuang Ho Medical Hospital, Taipei Medical University, Taipei, Taiwan disucss the rationale (...)

Metronomic chemotherapy : new rationale for new direction

Nat Rev Clin Oncol. 2010 Aug;7(8):455-65. Epub 2010 Jun 8. Metronomic chemotherapy: new rationale for new directions. Pasquier E, Kavallaris M, André N. Tumor angiogenesis is recognized as a major therapeutic target in the fight against cancer. The key involvement of angiogenesis in tumor growth and metastasis has started to redefine chemotherapy and (...)

Metronomic Chemotherapy : the book !

I t is our pleasure to announce the publication of the following book: Metronomic Chemotherapy : Pharmacology and Clinical Applications the editors are Guido Bocci and Giulio Francia With 19 chapters covering all fields of metronmic chemotherapy from the birth of the concept to updated clinical reviews. This book coversall aspects of metronomic (...)

Metronomic chemotherapy in advanced oral cancers

The Departments of Medical Oncology and Surgical Oncology of the Tata Memorial Hospital in Mumbai have just published in J Can Res Ther a study about the toxicity profile and efficacy of metronomic chemotherapy regimen (with twice daily celecoxib 200 mg and weekly methotrexate 15 mg/m2) for palliation in oral cavity cancers. Although not dealing with paediatric oncology this is a good exemple of what can metronomic chemotherapy can bring to patients in developing countries. Of note, Dr Banavali one of the authors of this article is also one of the Ambassador of MGHI

Metronomic cyclophosphamide & anti-tumor immunity: tumor model & drug schedule dependence of gene responses and their regulators.

In this recent preclinical work entitled Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators published in BMC Cancer, the team from David Waxman, Division of Cell and Molecular Biology, Department of Biology and Bioinformatics Program, Boston (...)